Search Results - "Trastuzumab/therapeutic use [MeSH]"

Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer

Authors: Charo Garrido Melissa Manoogian Dhiraj Ghambire et al.

Source: Virchows Arch

Subject Terms: Immunoconjugates, Female [MeSH], HER2-low, Receptor, ErbB-2/metabolism [MeSH], Humans [MeSH], Breast cancer, Breast Neoplasms/drug therapy [MeSH], Trastuzumab/therapeutic use [MeSH], Breast Neoplasms/metabolism [MeSH], Animals [MeSH], Camptothecin/analogs, Receptor, ErbB-2/analysis [MeSH], Camptothecin/therapeutic use [MeSH], Immunoconjugates/therapeutic use [MeSH], Original Article, Companion diagnostic, Reproducibility of Results [MeSH], Biomarkers, Tumor/metabolism [MeSH], Antineoplastic Agents, Immunological/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Biomarkers, Tumor/analysis [MeSH], 4B5, Immunohistochemistry/methods [MeSH], Breast Neoplasms/pathology [MeSH], Receptor, ErbB-2, Reproducibility of Results, Breast Neoplasms, Trastuzumab, Antibodies, Monoclonal, Humanized, Immunohistochemistry, 3. Good health, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Humans, Animals, Female, Camptothecin

Access URL: https://pubmed.ncbi.nlm.nih.gov/37857998
https://repository.publisso.de/resource/frl:6506949

Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland

Authors: Jeroen H. J. Paulissen Ahmed H. Seddik Kyle J. Dunton et al.

Source: Eur J Health Econ

Subject Terms: Adult, ddc:610, Original Paper, Immunoconjugates, Receptor, ErbB-2, Cost-Benefit Analysis, Breast Neoplasms, Trastuzumab, Middle Aged, Ado-Trastuzumab Emtansine, HER2-positive, Survival Analysis, 3. Good health, D61, Breast cancer, Antineoplastic Agents, Immunological, Cost-Benefit Analysis [MeSH], Receptor, ErbB-2/metabolism [MeSH], Cost-effectiveness, Trastuzumab/therapeutic use [MeSH], Metastatic, Camptothecin/analogs, Ado-Trastuzumab Emtansine/therapeutic use [MeSH], Camptothecin/therapeutic use [MeSH], Quality-Adjusted Life Years [MeSH], Finland [MeSH], Camptothecin/economics [MeSH], Breast Neoplasms/pathology [MeSH], Trastuzumab deruxtecan, Female [MeSH], Adult [MeSH], Humans [MeSH], Breast Neoplasms/drug therapy [MeSH], Survival Analysis [MeSH], Middle Aged [MeSH], Antineoplastic Agents, Immunological/economics [MeSH], Trastuzumab/economics [MeSH], Antineoplastic Agents, Immunological/therapeutic use [MeSH], Immunoconjugates [MeSH], Ado-Trastuzumab Emtansine/economics [MeSH], Humans, Female, Camptothecin, Quality-Adjusted Life Years, Finland

Access URL: https://pubmed.ncbi.nlm.nih.gov/37486557
https://research.rug.nl/en/publications/dc98b59b-1a54-47a0-a4b5-42f42ed50467
https://hdl.handle.net/11370/dc98b59b-1a54-47a0-a4b5-42f42ed50467
https://doi.org/10.1007/s10198-023-01617-3
https://hdl.handle.net/10419/318006
https://repository.publisso.de/resource/frl:6521759

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

Authors: Kuemmel S. Harper-Wynne C. Park Y. H. et al.

Source: BMC Cancer
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)

Subject Terms: Breast cancer, Estrogen receptor-positive, Giredestrant, HER2-positive, Pertuzumab, Trastuzumab, Adult, 0301 basic medicine, Receptor, ErbB-2, Injections, Subcutaneous, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Study Protocol, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Metastasis, RC254-282, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, 3. Good health, Receptors, Estrogen, Receptor, ErbB-2/metabolism [MeSH], Trastuzumab/administration, Antibodies, Monoclonal, Humanized/administration, Trastuzumab/therapeutic use [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Humans [MeSH], Neoplasm Metastasis [MeSH], Breast Neoplasms/genetics [MeSH], Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Injections, Subcutaneous [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Female

Access URL: https://pubmed.ncbi.nlm.nih.gov/38789924
https://doaj.org/article/e5f45a7c5b7e4bb7bb99b0bb30af3b2c
https://hdl.handle.net/11588/963524
https://repository.publisso.de/resource/frl:6504043

Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer

Authors: Jun Wang Na Sun Thomas Kunzke et al.

Source: Br J Cancer

Subject Terms: Treatment Outcome, Stomach Neoplasms, Receptor, ErbB-2, Receptor, ErbB-2/metabolism [MeSH], Humans [MeSH], Stomach Neoplasms/pathology [MeSH], Prospective Studies [MeSH], Treatment Outcome [MeSH], 631/67/1504/1829, Trastuzumab/therapeutic use [MeSH], Article, 631/67/2327, 631/67/2329, Prognosis [MeSH], 631/67/1059/602, article, Humans, Prospective Studies, Trastuzumab, Prognosis, ddc, 3. Good health

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/38267634
https://repository.publisso.de/resource/frl:6505910
https://mediatum.ub.tum.de/doc/1770257/document.pdf

Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells

Authors: Lukas Böckelmann Christin Starzonek Ann-Christin Niehoff et al.

Source: Histochem Cell Biol

Subject Terms: Original Paper, Paraffin Embedding, Tissue Fixation, Medizin, Cetuximab, Antineoplastic Agents, Trastuzumab, 3. Good health, Formaldehyde, DNA adduct, Trastuzumab/therapeutic use [MeSH], Cisplatin/analysis [MeSH], Antineoplastic Agents/analysis [MeSH], Tumor Cells, Cultured [MeSH], Cisplatin/therapeutic use [MeSH], Paraffin Embedding [MeSH], Rituximab/therapeutic use [MeSH], Doxorubicin/analysis [MeSH], Tissue Fixation [MeSH], Neoplasms/pathology [MeSH], Paraffin embedding, Formaldehyde/chemistry [MeSH], Cetuximab/analysis [MeSH], Humans [MeSH], Antineoplastic agents, Trastuzumab/analysis [MeSH], Tissue processing, Cetuximab/therapeutic use [MeSH], Cell pellet, Neoplasms/drug therapy [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Agar, Doxorubicin/therapeutic use [MeSH], Rituximab/analysis [MeSH], 03 medical and health sciences, 0302 clinical medicine, Doxorubicin, Neoplasms, Tumor Cells, Cultured, Humans, Cisplatin, Rituximab

Access URL: https://link.springer.com/content/pdf/10.1007/s00418-020-01857-x.pdf
https://pubmed.ncbi.nlm.nih.gov/32125512
https://www.ncbi.nlm.nih.gov/pubmed/32125512
https://link.springer.com/article/10.1007/s00418-020-01857-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225197
https://pubmed.ncbi.nlm.nih.gov/32125512/
https://link.springer.com/content/pdf/10.1007/s00418-020-01857-x.pdf
https://repository.publisso.de/resource/frl:6467540

A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)

Authors: Wege, Anja K. Kirchhammer, Nicole Kazandjian, Linda Veronique et al.

Source: J Transl Med
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-16 (2020)

Subject Terms: Monoclonal antibody, ddc:610, Anti-HER2 antibody, Breast cancer, Treatment efficiency, Humanized tumor mice, Monoclonal antibody, Receptor, ErbB-2, Anti-HER2 antibody, Research, 610 Medizin, Treatment efficiency, Apoptosis, Breast Neoplasms, Trastuzumab, 3. Good health, Mice, Breast cancer, Humanized tumor mice, Cell Line, Tumor [MeSH], Cell Proliferation [MeSH], Humans [MeSH], Breast Neoplasms/drug therapy [MeSH], Trastuzumab/therapeutic use [MeSH], Animals [MeSH], Apoptosis [MeSH], Mice [MeSH], Combination strategies, Receptor, ErbB-2 [MeSH], Rabbits [MeSH], Trastuzumab/pharmacology [MeSH], Cell Line, Tumor, Medicine, Animals, Humans, Rabbits, Cell Proliferation

File Description: application/pdf

Access URL: https://translational-medicine.biomedcentral.com/track/pdf/10.1186/s12967-020-02484-9
https://pubmed.ncbi.nlm.nih.gov/32799890
https://doaj.org/article/cd7cf64a32de421eaa9056447233790c
https://pubmed.ncbi.nlm.nih.gov/32799890/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429704
https://link.springer.com/article/10.1186/s12967-020-02484-9
http://www.ncbi.nlm.nih.gov/pubmed/32799890
https://www.ncbi.nlm.nih.gov/pubmed/32799890
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02484-9
https://repository.publisso.de/resource/frl:6464821
https://epub.uni-regensburg.de/44922/